

PLOS Medicine

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19

--Manuscript Draft--

Manuscript Number:	
Full Title:	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
Short Title:	Apolipoprotein-A1 decrease in Covid-19
Article Type:	Research Article
Section/Category:	Health Systems
Corresponding Author:	Thierry Poynard Assistance Publique - Hopitaux de Paris Paris, FRANCE
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Assistance Publique - Hopitaux de Paris
Corresponding Author's Secondary Institution:	
First Author:	Thierry Poynard
First Author Secondary Information:	
Order of Authors:	Thierry Poynard
	Olivier Deckmyn
	Marika Rudler
	Valentina Peta
	Yen Ngo
	Mathieu Vautier
	Sepideh Akhavan
	Vincent Calvez
	Clemence Franc
	Jean Marie Castille
	Fabienne Drane
	Mehdi Sakka
	Dominique Bonnefont-Rousselot
	Jean Marc Lacorte
	David Saadoun
	Yves Allenbach
	Olivier Benveniste
	Frederique Gandjbakhch
	Julien Mayaux
	Olivier Lucidarme
	Bruno Fautrel
	Vlad Ratziu
	Chantal Housset

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

	Dominique Thabut
	Patrice Cacoub
Order of Authors Secondary Information:	
Abstract:	<p>Findings</p> <p>During the 30 weeks of 2020 we observed in two large cohorts of patients at risk of liver fibrosis a highly significant decrease of serum apolipoprotein-A1, not observed in previous years. This decrease was highly correlated to and in parallel with the daily increase in confirmed Covid-19 cases, including the recovery period.</p> <p>Meaning</p> <p>Apolipoprotein-A1 could be used as a sentinel of the pandemic in existing routine surveillance of the general population.</p>
Additional Information:	
Question	Response
<p>Financial Disclosure</p> <p>Enter a financial disclosure statement that describes the sources of funding for the work included in this submission. Review the submission guidelines for detailed requirements. View published research articles from PLOS Medicine for specific examples.</p> <p>This statement is required for submission and will appear in the published article if the submission is accepted. Please make sure it is accurate.</p> <p>Unfunded studies Enter: <i>The author(s) received no specific funding for this work.</i></p> <p>Funded studies Enter a statement with the following details:</p> <ul style="list-style-type: none"> • Initials of the authors who received each award • Grant numbers awarded to each author • The full name of each funder • URL of each funder website • Did the sponsors or funders play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript? • NO - Include this sentence at the end of your statement: <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> • YES - Specify the role(s) played. 	<p>European Grant EIT health ProCoP 20879</p> <p>Patrice Cacoub</p>

<p>* typeset</p>	
<p>Competing Interests</p> <p>Use the instructions below to enter a competing interest statement for this submission. On behalf of all authors, disclose any competing interests that could be perceived to bias this work—acknowledging all financial support and any other relevant financial or non-financial competing interests.</p> <p>This statement will appear in the published article if the submission is accepted. Please make sure it is accurate. View published research articles from PLOS Medicine for specific examples.</p>	<p>I have read the journal's policy and the authors of this manuscript have the following competing interests:</p> <p>Thierry Poynard is the inventor of FibroTest, founder of BioPredictive, the patents belong to the public organization Assistance Publique-Hôpitaux de Paris. Olivier Deckmyn, Valentina Peta, Yen Ngo, Jean Marie Castille, Fabienne Drane and Clemence Franc are full employees of BioPredictive. The other authors have nothing to declare.</p>
<p>NO authors have competing interests</p> <p>Enter: <i>The authors have declared that no competing interests exist.</i></p> <p>Authors with competing interests</p> <p>Enter competing interest details beginning with this statement:</p> <p><i>I have read the journal's policy and the authors of this manuscript have the following competing interests: [insert competing interests here]</i></p>	
<p>* typeset</p>	

Cover letter

Dear Editor

We submit to PlosMedicine an article entitled “**Performance of serum apolipoprotein-A1 as a sentinel of Covid-19**”.


I share my professional life with apolipoprotein-A1 (ApoA1) since 1982, with a prospective cohort of 975 heavy French drinkers, followed by several other cohorts looking for fibrosis biomarkers.

In February 2020, serendipity scenario.

Our Hepatology department of Pitié-Salpêtrière, was transformed in a Covid-19 center and I rapidly observed in these severe patients a specific profile of Apo-A1 decrease and Haptoglobin increase, never observed before.

The night after, I realize that we have online more than 1 million of ApoA1 and Haptoglobin in the cohorts of patients followed by FibroTest for a risk of liver fibrosis. Therefore, we compared daily the ongoing year 2020 to previous years “Covid-Free”. Indeed, there was a highly significant decrease in ApoA1 parallel (2 weeks before) to the confirmed Covid-19 cases.

The most original result was that this decrease started few weeks before the incidence of confirmed cases, suggesting that ApoA1 detected infected cases. Furthermore, the liver function biomarkers as well as the Haptoglobin did not change so early.



We observed the normalization of apolipoprotein-A1 in the sera of the French cohort in June, in parallel with the decrease of daily confirmed Covid-19 cases, as well as the plateau in the US cohort.

Apolipoprotein-A1 could be a very simple early marker of the Covid-19 pandemic, as suggested in two ongoing surveillance databases, in France and USA with high sensitivity and specificity. It can be done immediately and with low cost in routine surveillance already dosing apolipoprotein-A1, as well as in patients with a clinical suspicion of Covid-19 but with a negative virologic test.

We do think that this article will help clinicians immediately, in the phase of a possible second wave, and epidemiologists for estimating the prevalence of infected subjects in general population, using other surveillance cohorts. Furthermore, our results suggest a potential intestinal transmission without liver signals.

This manuscript has not been presented or is not submitted elsewhere. None of the material concerning the large surveillance databases and the prospective observational cohort has been published or is under consideration for publication elsewhere.

According to the context of the pandemic, for assessing the specificity we used controls previously published in large studies of liver diseases. This permitted to have a wide spectrum of false positive risk. These measurements have been all performed on fresh serum collected prospectively and analyzed in the biochemistry unit of Pitié-Salpêtrière Hospital, Paris, France, with the same biochemical methods as for the prospective Covid-19 cases.

The prospective observational study in Covid-19 patients was approved by CER-Sorbonne University IRB, N° 2020–CER-2020-14, with a signed informed consent. Clinical investigation was conducted according to the principles of the Declaration of Helsinki. All authors had access to the study data and reviewed and approved the final manuscript. The components of Fibrotest and Nash-FibroTest were measured in routine in all patients with a risk of liver disease in France. The different databases integrated were used on sera anonymously. All the retrospective database analyses previously published either non-interventional study, without supplementary blood sample, were exempt from institutional review board (IRB) review (ethical committee of ‘Comité de Protection des Personnes of Paris, Ile-de-France’ FIBROFRANCE project. CPP-IDF-VI, 10– 1996-DR-964, DR-2012-222 and USA-NCT01927133).

This project was funded by the European Grant EIT health ProCoP 20879, Patrice Cacoub being the awarded author.

All the coauthors have reviewed this manuscript.

The data that support the findings of this study are fully available from the corresponding author, upon request.

I have a potential conflict of interest as the inventor of FibroTest, and founder of BioPredictive a spinoff company of Sorbonne University. The patent belongs to the French public organization Assistance Publique Hôpitaux de Paris.

Kind regards

Thierry Poynard

medRxiv preprint doi: <https://doi.org/10.1101/2020.09.01.20186213>; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19

Short title: Apolipoprotein-A1 decrease in Covid-19

Thierry Poynard^{1*}, Olivier Deckmyn^{2*}, Marika Rudler³, Valentina Peta², Yen Ngo², Mathieu Vautier⁴, Sepideh Akhavan⁵, Vincent Calvez⁶, Clemence Franc², Jean Marie Castille², Fabienne Drane², Mehdi Sakka⁶, Dominique Bonnefont-Rousselot⁶, Jean Marc Lacorte⁷, David Saadoun⁴, Yves Allenbach⁴, Olivier Benveniste⁴, Frederique Gandjbakhch⁹, Julien Mayaux¹⁰ Olivier Lucidarme¹¹, Bruno Fautrel⁹, Vlad Ratziu^{3,12}, Chantal Housset¹, Dominique Thabut³ and Patrice Cacoub⁴

Authors' affiliations

1. Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, INSERM, Centre de Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN)
2. BioPredictive, Research, Paris, France
3. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Hepatology, Paris, France
4. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Internal Medicine and Clinical Immunology, Paris, France
5. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Virology, Paris, France
6. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Metabolic Biochemistry, Paris, France
7. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Biochemistry, Endocrinology and Oncology, Paris, France
8. AP-HP Pitié-Salpêtrière, Sorbonne University, Institut of Cardiometabolism and Nutrition ICAN, Paris, France
9. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Rheumatology, Paris, France
10. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Intensive Care, Paris, France
11. AP-HP Pitié-Salpêtrière, Sorbonne University, Department of Radiology, Paris, France
12. INSERM Sorbonne University UMRS 1269 Nutriomique, service de Nutrition, APHP

*These authors contributed equally to this work.

Corresponding author: Thierry Poynard, Hepatology Groupe Hospitalier Pitie-Salpêtrière, 57 Bd Hôpital 75013 Paris, France. thierry@poynard.com . +(33) Tel: 142161022 Fax: 142161427

Funding source: Grant EIT health ProCoP 20879 Pr Patrice Cacoub APHP France

40 **Electronic word count:** 3,997 words (Including legends)

41

42 **Number of figures and tables:** 3 figures. 2 tables.

43

44 **Conflict of interest statement: a statement to declare any conflict of interest.**

45 Thierry Poynard is the inventor of FibroTest, founder of BioPredictive, the patents belong to
 46 the public organization Assistance Publique-Hôpitaux de Paris. Olivier Deckmyn, Valentina
 47 Peta, Yen Ngo, Jean Marie Castille, Fabienne Drane and Clemence Franc are full employees of
 48 BioPredictive. The other authors have nothing to declare.

49

50

51 **Authors' contribution**

52 Thierry Poynard, M.D. PhD (Conceptualization: Lead; Data curation: Equal; Formal analysis: Equal; Funding
 53 acquisition: Equal; Investigation: Equal; Methodology: Lead; Project administration: Lead; Resources: Equal;
 54 Supervision: Lead; Validation: Lead; Visualization: Lead; Writing – original draft: Lead; Writing – review &
 55 editing: Lead)

56 Olivier Deckmyn, PhD (Conceptualization: Equal; Data curation: Equal; Methodology: Equal; Software: Lead;
 57 Validation: Equal; Visualization: Equal; Writing – original draft: Equal; Writing – review & editing: Equal)

58 Marika Rudler, MD, PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)

59 Valentina Peta, PhD (Data curation: Equal; Investigation: Equal; Resources: Equal; Writing original draft: Equal;
 60 Writing review & editing: Equal)

61 Yen Ngo, MD PhD (Data curation: Equal; Investigation: Equal; Methodology: Equal; Validation: Equal)

62 Mathieu Vautier, MD (Data curation: Equal; Investigation: Equal; Resources: Equal)

63 Sepideh Akhavan, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal; Validation: Equal)

64 Vincent Calvez, MD PhD (Resources: Equal; Supervision: Equal; Validation: Equal)

65 Clemence Franc, MS (Formal analysis: Equal; Investigation: Equal; Writing – original draft: Equal)

66 Jean Marie Castille, PhD (Funding acquisition: Equal; Project administration: Equal; Validation: Equal)

67 Fabienne Drane, Ms (Investigation: Equal; Resources: Equal; Validation: Equal)

68 Mehdi Sakka, MD PhD (Investigation: Equal; Resources: Equal; Validation: Equal)

69 Dominique Bonnefont-Rousselot, Md PhD (Resources: Equal; Supervision: Equal; Validation: Equal)

70 Jean Marc Lacorte, MD PhD (Resources: Equal; Supervision: Equal; Validation: Equal)

71 David Saadoun, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)

72 Yves Allenbach, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)

73 Olivier Benveniste, MD PhD (Investigation: Equal; Resources: Equal; Supervision: Equal)

74 Frederique Gandjbakhch, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)

75 Julien Mayaux, MD PhD (Data curation: Equal; Investigation: Equal; Resources: Equal)

76 Olivier Lucidarme, MD PhD (Investigation: Equal; Resources: Equal; Validation: Equal)

77 Bruno Fautrel, MD PhD (Investigation: Equal; Resources: Equal; Supervision: Equal)

78 Vlad Ratzu, MD PhD (Formal analysis: Equal; Investigation: Equal; Resources: Equal)

79 Chantal Housset, MD PhD (Formal analysis: Equal; Supervision: Equal; Validation: Equal; Writing – original
 80 draft: Equal)

81 Dominique Thabut, MD PhD (Project administration: Equal; Resources: Equal; Supervision: Equal; Validation:
 82 Equal)

83 Patrice Cacoub, MD PhD (Conceptualization: Lead; Formal analysis: Lead; Funding acquisition: Equal;
 84 Investigation: Equal; Project administration: Lead; Resources: Equal; Supervision: Lead; Validation: Lead;
 85 Visualization: Lead; Writing – original draft: Equal; Writing review & editing: Equal)

86

87 **Key Points**

88 **Question:** Does serum apolipoprotein-A1 decrease could be a very early biomarker of SARS-
89 CoV-2 pandemic?

90 **Findings:** During the 30 weeks of 2020 we observed in two large cohorts of patients at risk of
91 liver fibrosis a highly significant decrease of serum apolipoprotein-A1, not observed in previous
92 years. This decrease was highly correlated to and in parallel with the daily increase in confirmed
93 Covid-19 cases, including the recovery period.

94 **Meaning:** Apolipoprotein-A1 could be used as a sentinel of the pandemic in existing routine
95 surveillance of the general population.

96

97 **ABSTRACT**

98 **Background**

99 Since 1920, a decrease in serum cholesterol has been identified as a marker of severe
100 pneumonia. We have assessed the performance of serum apolipoprotein-A1, the main
101 transporter of HDL-cholesterol, to identify the early spread of coronavirus disease 2019 (Covid-
102 19) in the general population and its diagnostic performance for the Covid-19.

103 **Methods**

104 We compared the daily mean serum apolipoprotein-A1 during the first 30 weeks of 2020 in a
105 population that is routinely followed for a risk of liver fibrosis risk in the USA (183,112 sera)
106 and in France (18,316 sera) in relation to a local increase in confirmed cases, and in comparison
107 to the same period in 2019 (respectively 234,881 and 26,056 sera). We prospectively assessed
108 the sensitivity of this marker in an observational study of 136 consecutive hospitalized cases
109 and retrospectively evaluated its specificity in 7,481 controls representing the general
110 population.

111 **Results**

112 The mean serum apolipoprotein-A1 levels in these populations began decreasing in January
113 2020, compared to the same 30 weeks in 2019. This decrease was highly correlated to and in
114 parallel with the daily increase in confirmed Covid-19 cases in the following 30 weeks, in both
115 France and USA, including the June and mid-July recovery periods in France. Apolipoprotein-
116 A1 at the 1.25 g/L cutoff had a sensitivity of 90.6% (95%CI84.2-95.1) and a specificity of
117 96.1% (95.7-96.6%) for the diagnosis of Covid-19. The area under the characteristics curve was
118 0.978 (0.957-0.988), and outperformed haptoglobin and liver function tests. The adjusted risk
119 ratio for survival without transfer to intensive care unit was 5.61 (95%CI 1.02-31.0;P=0.04).

120 **Conclusion**

121 Apolipoprotein-A1 could be both a sentinel of the pandemic in existing routine surveillance of
122 the general population with no new blood sample, as well as a candidate predictor of suspected
123 Covid-19 in multivariate analysis in cases with a negative virological test. NCT01927133,
124 CER-2020-14.

125

126 **Keywords:**

127 SARS-CoV-2; COVID-19; ApoA1; HDL-cholesterol; A2M; haptoglobin; ALT, GGT;
128 pandemic early biomarker; FibroFrance cohort

129

130

131 **Introduction**

132 There is an urgent need to detect people in the general population who are at risk of
133 being admitted to the hospital for Covid-19. Although viral nucleic acid testing and chest
134 computed tomography are standard methods for diagnosing Covid-19 in patients with
135 symptoms, these are time consuming. A review reported that there are only three models for
136 predicting hospital admission in the healthy general population, and these are limited by a high
137 risk of bias, and by using proxy outcomes.¹

138 In the meantime, several early detection tests of cytokine burst could be immediately
139 available. In 1920, Harold A. Kipp found that a decrease in serum cholesterol was a marker of
140 severe pneumonia.² One hundred years later, a meta-analysis confirmed that levels of high-
141 density lipoprotein cholesterol (HDL) and a level below the median of its transporter,
142 apolipoprotein-A1, was associated with a two-fold increase in mortality in patients with severe
143 sepsis (**supplementaryFig1,supplementaryTable1**).³ Its decrease seems to occur earlier than
144 the increase in haptoglobin, another marker of sepsis.^{4,5} Furthermore, unlike haptoglobin, which
145 is synthesized mainly by the liver, apolipoprotein-A1 is synthesized by both the liver and the
146 intestine.⁵ This hypolipidemia begins in Covid-19 patients with mild symptoms.^{6,7} Therefore,
147 in the general population, apolipoprotein-A1 might be a sensitive marker of infection in
148 asymptomatic subjects, in those without the pulmonary symptoms of standard Covid-19, or in
149 patients with an intestinal route of infection (**supplementaryFile1**).^{8,9}

150

151 **Methods.**

152 *Ethics*

153 The prospective observational study in Covid-19 patients was approved by CER-Sorbonne
154 University IRB,CER-2020-14, with a signed informed consent. All of the previously published
155 patient analyses from retrospective databases were non-interventional studies, without

156 supplementary blood samples, and were exempt from a review of the IRB
157 (NCT01927133,**supplementaryFile2**). The investigation was performed according to the
158 principles of the Declaration of Helsinki. All authors had access to the study data and reviewed
159 and approved the final manuscript.

160 *Decrease of apolipoprotein-A1*

161 We used three cohorts of sera from subjects at risk of liver fibrosis followed by FibroTest
162 (FibroSure in USA,**supplementaryFile2**),¹⁰ a large private-laboratories US cohort (“US-
163 cohort”), a cohort with an intermediate risk of Covid-19 (“French-cohort”) were patients being
164 followed in academic and private-laboratories, and a high-risk cohort which included patients
165 at the Pitié-Salpêtrière hospital Paris, France (“APHP-PSL”). The core temporal analysis
166 compared the first 30 weeks of consecutive anonymous sera 2020 vs. the sera 2019, from these
167 three routinely followed cohorts (**supplementaryFile2, supplementaryFig2C**).

168 *Confounding factors*

169 Decrease in apolipoprotein-A1 may be due to direct liver toxicity from SARS-CoV-2,¹¹ but also
170 to drug-induced liver disease (DILI) caused by medications (**supplementaryFile2,**
171 **supplementaryTable2**). We analyzed the kinetics of alpha2-macroglobulin (A2M) a specific
172 marker of liver fibrosis,¹⁰ and of haptoglobin, a sensitive biomarker of severe acute phase, as
173 well in the US-cohort of all the other components, according to non-alcoholic fatty liver disease
174 (NAFLD) sera, or chronic hepatitis C (HCV) sera(**supplementaryFile2**).

175 *Daily apolipoprotein-A1 and spread of Covid-19*

176 The number of confirmed Covid-19 cases in France and in the USA was assessed according to
177 published data from the European Centre for Disease Prevention and Control
178 (<https://ourworldindata.org/coronavirus-data>) (**supplementaryFig2A ,supplementaryFig2B**).

179 *Sensitivity and prognostic value*

180 Sensitivity was assessed in a prospective study of Covid-19 patients hospitalized in APHP-PSL,
181 described in **supplementaryFile2**. The primary endpoint was the survival without transfer in
182 ICU at 28 days, adjusted on age, gender, haptoglobin, and liver tests. (**supplementaryTable1**,
183 **supplementaryTable2,supplementaryFile1**).

184 *Specificity*

185 We collected prospective data on apolipoprotein-A1 from and since the first cohort of alcoholic
186 liver disease in 1982, and from the FibroFrance cohort (**supplementaryFile2**). More recently,
187 we collected six cohorts, which allowed us to retrospectively validate the specificity in a large
188 group of subjects (**supplementaryFile2**).¹²⁻¹⁶ The measurements were all performed on fresh
189 prospectively collected serum and analyzed in the biochemistry unit of the APHP-PSL hospital,
190 with the same methods as the Covid-19 cases (**supplementaryTable3**). The core control
191 population was a group of healthy volunteers that was representative of the French population.¹⁶
192 Forty-three patients without suspected Covid-19 were excluded (**supplementaryTable4**). In
193 order to identify a profile of patients with a possible intestinal route of infection, we compared
194 the subsets of patients with or without diarrhea.

195 Apolipoprotein-A1, haptoglobin, A2M, gammaglutamyl transpeptidase (GGT), alanine
196 aminotransferase (ALT) were assessed (**supplementaryTable2,supplementaryFile1**),
197 following BioPredictive (Paris, France) analytical recommendations.¹⁷ The virological methods
198 for the diagnosis used to diagnose SARS-CoV2 in respiratory samples, were detailed in
199 **supplementaryFile2**.

200 **Statistical methods**

201 The first primary endpoint was to demonstrate a significant decrease of the mean daily value of
202 apolipoprotein-A1 in the 30 weeks of the year 2020, vs. those of the year 2019. We defined a
203 significant decrease of apolipoprotein-A1 as below 1.25 g/L, the optimal cutoff defined by the
204 highest Youden index (sensitivity + specificity -1) in the severe patients. The daily proportion

205 of sera below this cutoff defined a significant risk of Covid-19. The second analysis was to
206 exclude confounding factors detailed in **supplementaryFile1**. We compared the linear
207 regression curves with 95% confidence intervals (95%CI) between the mean daily levels of all
208 markers, and the daily proportion of low apolipoprotein-A1, between the same 30 weeks
209 periods per year, by the *F*-test. A significant difference was defined as $P < 0.001$. The third
210 primary endpoint was to assess the association between the spread of Covid-19 and the decrease
211 in apolipoprotein-A1. The diagnostic performance of biomarkers was assessed using non-
212 parametric AUROCs. The prognostic values were assessed by survival curves, using Kaplan-
213 Meir method, compared by Logrank test (cutoff being the median of this context of use) and
214 adjusted by Cox model. The repeated sera assessments were compared by repeated ANOVA
215 and Tukey-Kramer multiple-comparison test. R and NCSS-2020 were used as statistical
216 software.

217
218

219 **Results**

220 *Decrease of apolipoprotein-A1*

221 The mean daily levels of apolipoprotein-A1 decreased globally (**fig1A**) and in the three cohorts
222 (**fig1B**; all $P < 0.001$), during the first 30 weeks of 2020. This was already highly significant in
223 January 2020 in the US-cohort (lower panel), compared to first 30 weeks of 2019 and 2018.
224 The mean daily proportion of sera with low apolipoprotein-A1 was 32.4% (95%CI 32.4-32.5)
225 on 30 weeks, that is 5.1% higher vs. 26.8% (27.2-27.4; $P < 0.001$) in 2019 (**fig1C**). There was no
226 significant difference between the years 2019 and 2018 for the daily mean globally (**fig1A**), or
227 by cohort (**fig1B**). The proportion of low apolipoprotein-A1, in 2018 was 26.5% (26.3-26.6),
228 that is a small 0.8% difference vs. the year 2019 (**fig1C**).

229 *Confounding factors*

230 The same significant kinetics in apolipoprotein-A1 levels were observed after stratification of
231 the regression curves for gender and age in the three cohorts (**supplementaryFig3**). The US-
232 cohort was the only sample that had the necessary power to compare these two factors together
233 between 2020 and 2019 and 2018 (**fig1D**), and in the subset of patients with HCV
234 (**supplementaryFig3C**). Apolipoprotein-A1 decrease was similar during Covid-19 spread
235 versus 2019 and 2018 in the US-cohort(**supplementaryFile2, supplementaryFig3**).

236 The kinetics of apolipoprotein-A1 were not associated with those of haptoglobin
237 (**supplementaryFig4**).

238 For A2M, there was in the US-cohort only a significant lower mean serum value, when
239 compared to 2019 and even more compared to 2018 (**supplementaryFig5A**), and detailed in
240 **supplementaryFig2, supplementaryFig5**), and highest in HCV vs. NAFLD sera. After
241 adjustment on age and gender there was no significant decrease of A2M between 2020 and
242 2019 (**supplementaryFig5**).

243 The other significant differences were, in the French-cohorts, GGT increased during the
244 pandemic peak and returned to previous years' value thereafter (**supplementaryFig6**), and an
245 increase in ALT in April 2020, in the US-cohort (**supplementaryFig7**).

246 No significant changes were observed for total cholesterol (**supplementaryFig8**), triglycerides
247 (**supplementaryFig9**), fasting glucose (**supplementaryFig10**), weight (**supplementaryFig11**)
248 and height (**supplementaryFig12**).

249 *Temporal associations between Covid-19 cases and apolipoprotein-A1*

250 The daily mean number of confirmed Covid-19 cases paralleled about 10 days after the daily
251 proportion of low apolipoprotein-A1 in sera. In USA, the first ten Covid-cases were declared
252 mid-January 2020, when the proportion of low apolipoprotein-A1 had already increase by
253 several percent (**fig1E**). The first peak of cases (n=50,000) was reached mid-April

254 **(supplementaryFig2B)**, and the first peak of low apolipoprotein-A1 (37.0%) on April 7th
255 **(fig1E, supplementaryFile2)**.

256 In France, the first ten Covid-cases were declared first week of March 2020
257 **(supplementaryFig2A)**, when the proportion of low apolipoprotein-A1 started to increase by
258 several percent **(fig1C)**. The first peak of cases (n=7,000) was reached mid-April
259 **(supplementaryFig2A)**, as well as the first peak of low apolipoprotein-A1 (40.0%) on April
260 14th **(fig1C, supplementaryFile2)**.

261 *Diagnostic performance of apolipoprotein-A1*

262 A total of 136 consecutive patients with severe Covid-19, but who did not require ICU were
263 include. Their characteristics and were similar to those published in such severity profiles
264 **(Table 2,supplementaryFile3)**.

265 The characteristics of patients included for the assessment of specificity are presented in
266 **supplementaryTable3**, the differences between characteristics of the subsets in
267 **supplementaryTable3**, in **fig2A** for the median value of apolipoprotein-A1 and in **fig2B** for
268 haptoglobin at inclusion.

269 The area under the characteristics curve (AUROC;95%CI) in 136 Covid-19 cases and 7,481
270 controls was 0.978(0.957-0.988), which outperformed haptoglobin and liver function tests
271 **(fig2C)**. Apolipoprotein-A1 at a cutoff of 1.25 g/L, had the best Youden index (86.7%) with a
272 sensitivity of 90.6%(84.2-95.1) and a specificity of 96.1%(95.7-96.6) for the diagnosis of
273 Covid-19.

274 For a prevalence of 1.8% (136/7617;1.5-2.1) of Covid-19 cases, the positive predictive value
275 was 30.0%(25.6-34.7) and the negative predictive value was 99.8%(99.7-99.9). The adjusted
276 predictive values according to prevalence predicted in the French population,¹⁶ were detailed
277 in **supplementaryFile2** as well as the specificity-sensitivity including blood donors
278 **(supplementaryFig12)**, and patients with rheumatological disease **(supplementaryFig13)**,

279 and the integrated six databases (**supplementary Fig14**), and the sensitivity in the 19 patients
280 with negative viral nucleic acid testing.

281 The prognostic value of apolipoprotein-A1 at inclusion for predicting the primary outcome was
282 significant, risk-ratio (RR;95%CI) =5.61 (1.02-31.0;P=0.04), adjusted on age (1.04;1.01-
283 1.07;P=0.04), GGT (2.88;1.01-8.19;P=0.04). The 71 patients with apolipoprotein-A1
284 value \geq 0.84 g/L, the median value at inclusion, had a significant higher survival without ICU
285 (93.0%;87.0-98.9) than the 65 patients with lower value (75.8%; 65.1-86.5; P=0.02) (**fig2D**).

286 Repeated assessments of 305 sera (**supplementary Fig15**) showed that in patients who survived
287 without ICU, the mean apolipoprotein-A1 raised significantly already at 10 days, as well as the
288 16 patients who survived after their transfer to ICU.

289 The prevalence of diarrhea on initial presentation was 29 out of 131 cases (22.1%;95%CI 15.4-
290 30.2). In this subset, the only significant difference was a lower median number of polynuclear
291 leucocytes (**supplementary Table5, supplementary File2**).

292
293
294

Discussion

295 Our study shows in three cohorts of patients at risk of liver fibrosis, that apolipoprotein-A1 had
296 a highly significant decrease in 2020 vs previous years, and a highly significant negative daily
297 time-related association with the number of Covid-19 cases. Apolipoprotein-A1 decrease had
298 a high sensitivity in prospective hospitalized patients, with a high specificity in retrospective
299 controls, and an independent prognostic value for the survival without transfer to ICU. These
300 results have certain strengths and limitations.

Decrease of apolipoprotein-A1 in 2020

302 The originality of these results was not the decrease in apolipoprotein-A1 during the peak of
303 the pandemic in April, as very low levels of HDL-cholesterol in sera collected in Covid-19
304 were known in severe pneumonia since 1920 (**supplementary Table1**).² More intriguing was

305 the very early decrease observed since January 2020 in the USA when the number of Covid-19
306 cases was unknown. The first known Covid-19 patient was detected on 27/12/2019 and
307 19/01/2020 in France and the USA, respectively(**supplementaryFile3**). The larger sample size
308 of the US surveillance population, compared to the French, allowed detection of a significant
309 1% increase in the proportion of subjects possibly infected using the 1.25 g/L cutoff in January
310 (**fig1C**), without any inflammatory signal using haptoglobin. We hypothesized that the SARS-
311 CoV2 virus influenced the liver or intestinal synthesis of apolipoprotein-A1, in asymptomatic
312 patients or in those with unusual mild symptoms.

313 *Confounding factors*

314 The decrease of apolipoprotein-A1 in 2020 vs. previous years, as well as the time-related
315 association of apolipoprotein-A1 in 2020 and Covid-19 might be due to numerous confounding
316 factors. In the context of the pandemic we used cohorts of subjects requiring surveillance of
317 liver fibrosis biomarkers which represent at least 30% of the general adult population in the
318 USA and in France. In these cohorts 70% of the subjects had no or minimal fibrosis. The
319 decrease in apolipoprotein-A1 in 2020 compared to 2019, and 2018 cannot be explained by bias
320 due to gender, age, the cause of liver disease (**table1, supplementaryFile3**), and the severity
321 of liver diseases (**supplementaryFile4**). The prevalence of severe cases cannot explain the
322 significant decrease in apolipoprotein-A1 already observed in January 2020. GGT a very
323 sensitive liver biomarkers did not change during the first 3 months (**supplementaryFig6**).
324 Finally, in these severe liver diseases, haptoglobin should be also significantly decreased
325 (**fig2A**), which was not observed.

326 In the US-cohort the proportion of sera with NAFLD was increased by 1.8% in 2020 vs 2019
327 (**table1**). However, after stratification for age and gender, no significant changes were observed
328 for all other biomarkers (**supplementaryFig8,supplementaryFig9,supplementaryFig10,**
329 **supplementaryFig11,supplementaryFile12**). ALT was the only biomarker of the liver tests

330 which increased significantly at the 15th week of 2020, above the usual mean value observed in
331 2019 (**supplementaryFile7**). This increase in ALT was not associated with any other changes
332 (**supplementaryFig10, supplementaryFig11, supplementaryFig12**). We have no clear
333 explanation. We hypothesize that another confounding factor could be a DILI, including oral
334 acetaminophen or hydroxychloroquine misuse during the pandemic. Such factor could explain
335 an increase in ALT, without increase in haptoglobin, in subjects with mild symptoms.
336 The absence of haptoglobin change (**supplementaryFig4**) associated with the linear
337 apolipoprotein-A1 decrease (**fig1B**), has never been described before. It was known that in
338 patients with severe fibrosis these two proteins decrease.¹⁰ It was also known that in severe
339 pneumonia the haptoglobin increase was associated to the apolipoprotein-A1 decrease
340 (**supplementaryTable1**), as we observed in the cohorts with high prevalence of severe Covid-
341 19 (**fig2B**)(**supplementaryFile3**). The 30 weeks followup permitted to see the return to normal
342 values of haptoglobin in these cohorts, associated to the decrease of severe Covid-19 cases
343 admissions (**supplementaryFig4A**). Furthermore, the recovering patients followed by repeated
344 sera in the prospective study, had both a significant increase of apolipoprotein-A1
345 (**supplementaryFig15B**) and a significant decrease in haptoglobin (**supplementaryFig15D**),
346 10 days after inclusion.

347 *Temporal associations between Covid-19 confirmed cases and apolipoprotein-A1 decrease*

348 Our results (**fig1C**) suggest that the spread of the pandemic in the US-cohort would be at least
349 around 5.6%, and at least of 4.3% in the French-cohort. In France, this estimate does not differ
350 from the recent French model that predicted a rate of infection of between 2.8% to 7.2% in the
351 general population.¹⁸

352 This temporal association of low apolipoprotein-A1 with the number of confirmed cases,
353 persisted in the two different pandemic changes. In France, after the national lockdown the
354 proportion of low apolipoprotein-A1 returned to the cohort usual 2018-2019 values in June

355 together with the dramatic regression of confirmed cases, still maintained in July. In the US,
356 the apolipoprotein A1 and confirmed cases had the same kinetics with the dramatic increase in
357 April and a plateau in June, still ongoing in July (**fig1E**).

358 *Specificity of apolipoprotein-A1*

359 There is a high risk of overestimating the specificity of a test in Covid-19 when the participants
360 enrolled in the studies might not be representative of targeted populations.¹ However, our
361 previous cohorts of patients with severe liver diseases allowed us to identify the major risks of
362 a significant decrease in apolipoprotein-A1 (false positives), mainly due to severe hepatic
363 insufficiency and severe fibrosis. An impact of malnutrition on apolipoprotein-A1 values, was
364 not possible as no changes in weight and height were observed.

365 *Sensitivity of apolipoprotein-A1*

366 There is also a high risk of overestimating the sensitivity.¹ It is difficult to confirm the
367 sensitivity for asymptomatic infection, due to the absence of validations of SARS-CoV2-
368 antibodies. To validate the sensitivity of apolipoprotein-A1, a large number of asymptomatic
369 “apparently healthy” subjects who are positive for SARS-CoV-2 viral nucleic acid testing is
370 needed. Our patients included with Covid-19 symptoms had a median of 70 years of age and
371 were severe enough to justify admission to hospital, but none of them required mechanical
372 ventilation at admission, 86% survived, only 6% were transferred to the intensive care unit, and
373 9% died (**table1**). The sensitivity in the prospective part of our study was similar in the 19
374 patients who were negative for viral nucleic acid testing (94.7%) to that in positive patients
375 (89.9%). Thus, a simple measurement of apolipoprotein-A1 could be useful for clinicians due
376 to the high percentage of false negatives in available viral nucleic acid testing.¹⁸ Apolipoprotein-
377 A1 or HDL-cholesterol are already being assessed in many large ongoing studies in patients
378 with chronic diseases, which could rapidly validate our results.

379 *Prognostic performance*

380 The univariate prognostic value of apolipoprotein-A1 was confirmed (**fig2D**) but to our
381 knowledge, it was the first time that its prognostic value persisted after adjustment by age, a
382 marker of acute inflammation (haptoglobin), a sensitive marker of liver injury (GGT), and a
383 marker of liver fibrosis (A2M). Among patients with recovery, there was a significant increase
384 of apolipoprotein-A1 10 days after admission (**supplementaryFig15**). Therefore,
385 apolipoprotein-A1 measurement could help for the decision to transfer to ICU.

386 *Mechanisms of the early decrease in apolipoprotein-A1 before recognition of the pandemic*

387 We never observed such profile of biomarkers in our experience since 2001 with more than
388 three million of FibroTest assessed in liver diseases (**supplementaryFile1**).^{10,12-17}

389 Although the mechanisms explaining the decrease in apolipoprotein-A1 in late severe Covid-
390 19 pneumonia are known (**supplementaryTable1**), the reason for the early decrease before the
391 acute phase, when haptoglobin remained normal is unclear. In patients with severe pneumonia,
392 apolipoprotein-A1 decrease was associated with acute inflammation and the “cytokine storm”
393 with an increase in IL6 and acute phase proteins such as CRP and haptoglobin. This dissociation
394 suggests that different mechanisms play a role in the early influence of the SARS-CoV2 virus
395 on the synthesis of apolipoprotein-A1, and the intestine could be more involved than the liver.
396 The SARS-CoV2 virus could impact several pathways leading to a decrease in the intestinal
397 synthesis and absorption of apolipoprotein-A1 in the small intestine resulting in the decrease in
398 serum.³⁻⁹ These mechanisms are discussed in **supplementaryFile1**. The first could be the
399 inhibition of lysophosphatidylcholine-acyltransferase-3 activity. There is evidence of direct
400 SARS-CoV2 infection of the endothelial cell and diffuse endothelial inflammation in the
401 intestine.^{7,8,9} SARS-CoV2 uses angiotensin-converting enzyme-2 receptor (ACE-2) expressed
402 on endothelial cells, to infect the host, widely expressed in the lung, intestine and liver.^{9,20} The
403 second mechanism could be an impact of the virus through the intestinal mucus.²¹
404 Apolipoprotein-A1 is released as a free apolipoprotein from the apical side of enterocytes into

405 the lumen in the fasting state. Apolipoprotein-A1 had faster turnover in mucus, which could be
406 a target for SARS-CoV2.^{7,8,21}

407 ***Conclusion***

408 Despite the limitations of this study, these results suggest that apolipoprotein-A1 could
409 be a component of multi-analyte Covid-19 diagnostic and prognostic tests. It could also help to
410 manage patients with a clinical suspicion of Covid-19 and a negative virological test. These
411 results must be validated in independent large cohorts, ideally with virologic and efficiency
412 endpoints. The role of SARS-CoV2 in the possible “asymptomatic” decrease in apolipoprotein-
413 A1 could be related to intestinal infection without or before overt pulmonary disease. Finally,
414 one hundred years after surrogate sentinel HDL-cholesterol for pneumonia,² apolipoprotein-A1
415 for the second time in a century, could be “one of the early warning systems that alert the world
416 to potential outbreaks”.²²

417 **References**

- 418 1. Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and prognosis
419 of Covid-19 infection: systematic review and critical appraisal. *BMJ* 2020;**369**:m1328.
- 420 2. Kipp HA. Variation in the cholesterol content of the serum in pneumonia. *J Biol Chem* 1920;
421 **44**:215-237.
- 422 3. Liu SH, Liang HY, Li HY, et al. Effect of low high-density lipoprotein levels on mortality
423 of septic patients: A systematic review and meta-analysis of cohort studies. *World J Emerg*
424 *Med* 2020;**11**:109–116.
- 425 4. Delanghe JR, Langlois MR, Boelaert JR, et al. Haptoglobin polymorphism, iron metabolism
426 and mortality in HIV infection. *AIDS* 1998;**12**:1027-32.
- 427 5. Yang H, Wang H, Wang Y, et al. The haptoglobin beta subunit sequesters HMGB1 toxicity
428 in sterile and infectious inflammation. *J Intern Med* 2017;**282**:76-93.
- 429 6. Wei X, Zeng W, Su J, et al. Hypolipidemia is associated with the severity of COVID-19. *J*
430 *Clin Lipidol.* 2020;**14**:297- 304.
- 431 7. Cao X, Yin R, Albrecht H, et al. Cholesterol: A new game player accelerating endothelial
432 injuries caused by SARS-CoV-2? *Am J Physiol Endocrinol Metab.* 2020;**319**:E197-E202.
433
- 434 8. Lamers MM, Beumer J, van der Vaart J, et al. SARS-CoV-2 productively infects human
435 gut enterocytes. *Science.* 2020; eabc1669.
436
- 437 9. Ding S, Liang TJ. Is SARS-CoV-2 Also an enteric pathogen with potential fecal-oral
438 Transmission? A COVID-19 virological and clinical review. *Gastroenterology*
439 2020;**159**:53-61.
- 440 10. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients
441 with hepatitis C virus infection: a prospective study. *Lancet* 2001; **357**:1069-75.
- 442 11. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet*
443 *Gastroenterol Hepatol* 2020; **5**:428-430.
- 444 12. Peta V, Tse C, Perazzo H, et al. Serum apolipoprotein A1 and haptoglobin, in patients with
445 suspected drug-induced liver injury (DILI) as biomarkers of recovery. *PloS One* 2017;
446 **12**:e0189436.
- 447 13. Rudler M, Mouri S, Charlotte F, et al. Validation of AshTest as a non-invasive alternative
448 to transjugular liver biopsy in patients with suspected severe acute alcoholic hepatitis. *PLoS*
449 *One* 2015; **10**:e0134302.
- 450 14. Perazzo H, Pais R, Munteanu M, et al. Variability in definitions of transaminase upper limit
451 of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic
452 hepatitis C: "APRI c'est fini ?". *Clin Res Hepatol Gastroenterol* 2014; **38**:432- 439.

medRxiv preprint doi: <https://doi.org/10.1101/2020.09.01.20186213>; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

- 453 15. Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis
454 and prognosis of drug-induced liver injury: An international collaborative effort. *Hepatology*
455 2019; **69**:760-773.
- 456 16. Poynard T, Lebray P, Ingiliz P, et al. Prevalence of liver fibrosis and risk factors in a general
457 population using non-invasive biomarkers (FibroTest). *BMC Gastroenterol* 2010; **10**:40.
- 458 17. Poynard T, Munteanu M, Deckmyn O, et al. Applicability and precautions of use of liver
459 injury biomarker FibroTest. A reappraisal at 7 years of age. *BMC Gastroenterol.* 2011;**11**:39.
- 460 18. Salje H, Tran Kiem C, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France
461 2020;368:6498. *Science.* 2020;eabc3517.
- 462 19. Li Y, Yao L, Li J, et al. Stability issues of RT-PCR testing of SARS-CoV-2 for
463 hospitalized patients clinically diagnosed with COVID-19. *J Med Virol* 2020; **92**:903-908.
464
- 465 20. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the
466 epithelial cells of oral mucosa. *Int J Oral Sci* 2020;**12**:8.
467
- 468 21. Danielsen EM, Hansen GH, Rasmussen K, et al. Apolipoprotein A-1 deposition in, and
469 release from, the enterocyte brush border: a possible role in transintestinal cholesterol efflux
470 (TICE)? *Biochim Biophys Acta* 2012; **1818**:530- 536.
- 471 22. Gates B. Responding to Covid-19.A Once-in-a-Century Pandemic? *New Engl J Med* 2020;
472 **382**:1677-1679.
- 473

474
475**Table1.** Characteristics of the sera included in US and French-cohorts

Characteristics	2020	2019	P-Value
US-cohort	N=183,112	N=234,881	
Median age [IQR]	54.1 [40.4-63.3]	55.0 [41.7-63.3]	<0.001
Age category n (%)			<0.001
< 50 year	75,782(41.4)	90,853 (38.5)	
50 to <70 year	88,597 (48.4)	121,757 (51.8)	
>= 70 year	18,733 (10.2)	22,771 (9.7)	
Male sex (%)	103,672 (56.6)	131,056 (55.8)	<0.001
Apolipoprotein-A1<1.25 g/L (%)	59,419 (32.4)	62,898 (26.8)	<0.001
Median laboratory (IQR)			
Apolipoprotein-A1 g/L	1.37 [1.19-1.58]	1.41 [1.23-1.68]	<0.001
Haptoglobin g/L	1.23 [0.82-1.68]	1.23 [0.82-1.69]	0.72
Alpha-2-macroglobulin g/L	2.16 [1.65-2.93]	3.07 [1.70-3.07]	<0.001
GGT IU/L	36 [21-77]	38 [21-79]	0.87
ALT IU/L ¹	38 [22-70]	38 [23-68]	<0.001
Total bilirubin micromol/L	6.84 [5.13-10.26]	6.84 [5.13-10.26]	0.01
Fibrosis stage by FibroTest (%)			<0.001
F0	94,170 (51.4)	116,666 (49.7)	
F1	36,738 (20.1)	47,123 (20.1)	
F2	13,330 (7.3)	17,834 (7.6)	
F3	17,914 (9.8)	24,514 (10.4)	
F4	19,648 (10.7)	27,030 (11.5)	
Non interpretable	1,312 (0.7)	1,714 (0.7)	
NAFLD (surveillance by NASH-FibroTest) ²	N=37,298 (20.2)	N=42,271 (18.0)	<0.001
Weight (Kg)	88.9 (74.8-105.2)	88.5 (74.8-104.3)	0.003
Aspartate amino transferase (AST)	34 (25-52)	34 (25-52)	0.55
Total cholesterol	4.53 (3.80-5.33)	4.53 (3.80-5.28)	0.001
Triglycerides	1.57 (1.13-2.24)	1.55 (1.11-2.21)	0.02
Fasting glucose	5.67 (5.06-6.89)	5.61 (5.06-6.78)	<0.001
Table 3 continued			
French-cohort	N= 18,316	N=26,056	
Median age [IQR]	51.5 (41.2-64.4)	52.6 (39.7-63.1)	<0.001
Age category n (%)			<0.001
< 50 year	7,514 (40.9)	11,517 (44.2)	
50 to <70 year	8,187 (44.4)	11,340 (43.5)	
>= 70 year	2,615 (14.3)	3,199 (14.3)	
Male sex (%)	10,619 (58.0)	14,908 (57.2)	<0.001
Apolipoprotein-A1<1.25 g/L (%)	5,694 (31.1)	7,057 (27.1)	<0.001
Median laboratory (IQR)			
Apolipoprotein-A1 g/L	1.38 (1.20-1.59)	1.40 (1.23-1.61)	<0.001
Haptoglobin g/L	1.18 (0.79-1.62)	1.15 (0.78-1.57)	<0.001
Alpha-2-macroglobulin g/L	1.96 (1.52-2.61)	2.01 (1.56-2.69)	<0.001
GGT IU/L	36 (21-79)	34 (20-73)	<0.001
ALT IU/L	31 (21-50)	31 (21-50)	0.42
Total bilirubin micromol/L	8.7 (6-12)	8.7 (6-12)	0.20
Fibrosis stage by FibroTest (%)			<0.001
F0	9,437 (51.5)	13,671 (52.5)	
F1	4,080 (22.3)	5,708 (21.9)	
F2	1,328 (7.3)	1,877 (7.2)	
F3	1,664 (9.1)	2,263 (8.7)	
F4	1,655 (9.0)	2,336 (9.0)	
Non interpretable	190 (0.8)	201 (0.8)	
NAFLD (surveillance by NASH-FibroTest) ²	4152 (19.2)	6,110 (20.4)	<0.001
Weight	83 (71-97)	83 (71-97)	0.41
Aspartate amino transferase (AST)	30 (23-42)	30 (23-41)	0.47
Total cholesterol	4.79 (4.00-5.55)	4.75 (4.00-5.62)	0.30
Triglycerides	1.37 (1.00-1.96)	1.40 (1.00-2.00)	0.02

Fasting glucose	5.76 (5.15-6.98)	5.72 (5.17-6.90)	0.87
-----------------	------------------	------------------	------

476 ¹ Not normal distribution, the means of ALT were in 2020 43.4 IU/L vs 42.7 IU/L in 2019

477 ² NASH-FibroTest included more components than FibroTest: weight, aspartate aminotransferase, total
478 cholesterol, triglycerides, and fasting glucose

479

480
481**Table 2.** Characteristics of Covid-19 patients of the prospective study.

Characteristics	COVID-19 diagnostic		P value	Total
	PCR positive	PCR negative Adjudicated		
Number n (%)	117 (100%)	19 (100%)		136
Median age (IQR) year	72 (57-82)	65.1 (49-74)	0.15	72 (59-83)
Age category			0.16	
<50 year	14 (12.0)	5 (26.4)		19 (14.0)
50 to <70 year	37 (31.6)	7 (36.8)		44 (32.3)
>=70 year	66 (56.4)	7 (36.8)		73 (53.7)
Male sex	66 (56.4)	12 (63.2)	0.58	78 (57.4)
Geographic origin			0.53	
Caucasian	67 (57.3)	14 (73.7)		81 (59.6)
Subsaharan	17 (14.5)	1 (5.3)		18 (13.2)
North African, Middle East	20 (17.1)	2 (10.5)		22 (16.9)
Asian	13 (11.1)	2 (10.5)		15 (11.0)
Oxygen-support category			0.75	
Invasive oxygen support	0	0		0 (0-0)
Noninvasive oxygen support	82 (70.1)	14 (73.7)		96 (70.6)
None	35 (29.9)	5 (26.3)		40 (29.4)
Coexisting conditions				
Hypertension	65 (55.6)	9 (47.4)	0.51	74 (54.4)
Diabetes	32 (27.4)	3 (15.8)	0.29	35 (25.7)
Hyperlipidemia	32 (27.4)	7 (36.8)	0.40	39 (28.7)
Liver disease	11 (9.4)	4 (21.1)	0.13	15 (11.03)
Pulmonary disease	13 (11.6)	1 (5.6)	0.44	14 (10.8)
Severe disease associated	64 (55.2)	11(57.9)	0.82	75 (55.6)
Tobacco (ongoing or stopped)	35 (29.9)	8 (42.1.3)	0.29	43 (31.6)
Alcohol consumption	15 (12.9)	5 (26.3)	0.13	20 (14.8)
Initial presentation				
Anosmia (13 missing)	12 (11.1)	3 (20.0)	0.32	15 (12.2)
Ageusia (13 missing)	16 (14.8)	3 (20.0)	0.60	19 (15.5)
Headache (13 missing)	10 (9.3)	4 (26.7)	0.05	14 (11.4)
Dyspnea (12 missing)	59 (54.1)	8 (53.3)	0.95	67 (54.0)
Wheezing (12 missing)	3 (2.75)	0 (0.00)	0.52	3 (2.42)
Cough without spitting (12 missing)	47 (43.1)	6 (40.0)	0.82	53 (42.7)
Cough with spitting (12 missing)	18 (16.5)	2 (13.3)	0.75	20 (16.1)
Fatigue	61 (56.5)	8 (53.3)	0.82	69 (59.1)
Time clinic-inclusion (days)	8 (5-13.8)	11 (9-16.5)	0.13	9 (5-14)
Followup (days)	38 (27-53)	28 (26-36)	0.05	32 (27-49)
BMI (Kg/m ²)	25 (23-29)	24 (22-28)	0.56	25 (23-28)
Apolipoprotein <= 1.25g/L	104 (88.9)	19 (100)	0.13	123 (90.4)
Median laboratory (IQR)				
Apolipoprotein-A1 g/liter	0.85 (0.73-1.06)	0.74 (0.61-0.87)	0.06	0.84 (0.70-1.03)
Haptoglobin g/liter	3.16 (2.20-4.19)	3.18 (1.59-3.86)	0.59	3.16 (2.22-4.08)
Alpha-2 macroglobulin g/liter	1.49 (1.24-2.06)	1.46 (1.12-2.01)	0.41	1.49 (1.22-2.05)
GGT IU per liter	47 (28-114)	58 (32-102)	0.27	49 (30-114)
ALT IU per liter	29 (20-47)	40 (15-57)	0.80	31 (20-51)
Total bilirubin micromol/L	7 (6-8)	9 (8-13)	0.01	8 (5-12)
Platelets 10 ⁶ per ml	211 (162-278)	279 (194-330)	0.06	221 (164-287)
Creatinine μmol per liter	78 (62-103)	78 (70-120)	0.97	78 (63-103)
Fasting glucose	6 (5.4-8.0)	6.6 (5.2-7.9)	0.38	6.1 (5.4-7.9)
Albumin g/L (18 missing)	31(27-33)	29 (27-39)	0.89	30 (27-33)
Procalcitonin (17 missing)	0.13 (0.08-0.27)	0.14 (0.09-0.23)	0.98	0.13 (0.09-0.27)
C-reactive protein (13 missing)	56 (20.3-95.6)	101 (15.4-252.9)	0.21	59 (20.3-102.3)
InterLeukin-6 (38 missing)	31 (13.5-55.2)	29 (8.05-119)	0.96	31 (12.3-55.5)
CPK (18 missing)	101 (51.5-243.3)	47.5 (37.5-127)	0.05	94 (45.8-233)
AST (11 missing)	44 (30-60)	34 (25-42)	0.04	41 (30-59)
LDH (16 missing)	347 (278-419)	353 (289-440)	0.68	347 (278-420)
D-dimer (24 missing)	1050 (550-2030)	1570 (1140-3980)	0.09	1125 (570-2158)
Troponin (14 missing)	16.4 (9.85-34.63)	17.2 (9.56-36.5)	0.99	16.4 (9.85-34.63)
Prothrombin time (16 missing)	92 (83-100)	82 (39-89)	0.005	90 (81-100)
White cells				
Neutrophil missing (14 missing)	4185 (2773-6145)	5945 (3963-7550)	0.05	4420 (2928-6200)
Eosinophil (12 missing)	0 (0-30)	10 (0-150)	0.14	0.05 (0-30)

medRxiv preprint doi: <https://doi.org/10.1101/2020.09.01.20186213>; this version posted September 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Lymphocyte (14 missing)	965 (670-1295)	1150 (798-1700)	0.25	975 (685-1295)
Hemoglobin g/L (12 missing)	12 (11.2-13.6)	12 (10.5-14.7)	0.64	12 (11.1-13.8)
Treatment at risk of DILI				
Paracetamol oral (2-4 g/day)	43 (36.8)	5 (26.3)	0.38	48 (35.3)
Antibiotics	91 (77.8)	15 (78.9)	0.91	106 (77.9)
None	26 (22.2)	4 (21.1)		30 (22.1)
Without clavulinate	49 (41.9)	5 (26.3)		54 (39.7)
Whit clavulinate	68 (58.1)	14 (73.7)		82 (60.3)
Steroids	12 (10.3)	1 (5.3)	0.49	13 (9.56)
Hydroxy chloroquine	47 (40.1)	6 (31.6)	0.48	53 (39.0)
No Intensive care no death	99 (84.6)	17 (89.5)	0.23	116 (85.3)
Transfer intensive care unit	18 (15.4)	2 (10.5)	0.58	20 (14.7%)
Death (4 in intensive care unit)	15 (12.8)	1(5.3)	0.34	16 (11.8)

482

483

484

485 **Figures legends**

486

487 **Fig1. Decrease of apolipoprotein-A1 value in the first 30 weeks of 2020.**

488 **1A Global decrease of apolipoprotein-A1 among the sera of patients with risk of liver**
489 **fibrosis in the first 30 weeks of 2020 in USA and France compared to the two previous**
490 **years (P<0.001).**

491 **1B Quantitative decrease of apolipoprotein-A1 by cohort.** Apolipoprotein-A1 decreased
492 (P<0.001) in the three cohorts, starting early in January 2020 (red line with 95% confidence
493 interval) in the US cohort (lower panel).

494 **1C Proportion of serum with low apolipoprotein-A1 by cohorts.** Low apolipoprotein-A1
495 was defined as below 1.25 g/L. Details in supplementaryFile2.

496 **1D Decrease of apolipoprotein-A1 by gender and age in US cohort.** The same significant
497 kinetics were observed, P<0.001 between 2020 and previous years.

498 **1E Number of confirmed Covid-19 cases per day and proportion of low (<1.25g/L)**
499 **apolipoprotein-A1 in the US cohort during the first 30 weeks of 2020.**

500 The red graph is the number of confirmed cases per day in logarithmic scale. The black line is
501 the daily mean proportion of low apolipoprotein-A1 (<1.25g/L; blue line;95%CI in grey).

502

503 **Fig 2. Performances of apolipoprotein-A1 and haptoglobin for the diagnostic and**
504 **prognostic of Covid-19 patients.** Details in supplementaryFile2.

505 **Fig2A.** Apolipoprotein-A1 median with IQR between the 6 populations


506 **Fig2B.** Haptoglobin CPAM: general population ASH: severe acute alcoholic hepatitis, DILI:
507 drug induced liver disease, RHE: rheumatologic disease, BD: blood donors.


508 **Fig2C.** AUROCs of each FibroTest components.


509 **Fig2D.** Survival without transfer to intensive care unit (ICU).


510 The 71 patients with apolipoprotein-A1 value ≥ 0.84 g/L, the median value at inclusion, had
511 a significant higher survival without ICU (93.0%;87.0-98.9) than the 65 patients with lower
512 value (75.8%;65.1-86.5;P=0.02).


513




















ApoA1 >= 0.84	71 0 0	70 0 1	69 0 3	66 1 5	60 9 5
ApoA1 < 0.84	65 0 0	60 1 6	55 2 8	51 4 12	40 17 15



[Click here to access/download](#)

Supporting Information - Compressed/ZIP File Archive
Supplementary material V22 TP.docx.zip

